Introduction and reflection on the clinical practice guideline for the treatment of hypercalcemia of malignancy in adults

VernacularTitle:对成人恶性肿瘤高钙血症治疗临床实践指南的介绍和思考
Author: Yuying YANG ¹ ; Minting ZHU ; Lihao SUN ; Jianmin LIU
Author Information

1. 上海交通大学医学院附属瑞金医院内分泌代谢病科，上海市内分泌代谢病研究所，国家代谢性疾病临床医学研究中心　200025
Keywords: Hypercalcemia; Malignant tumor; Treatment
From: Chinese Journal of Endocrinology and Metabolism 2023;39(10):821-825
CountryChina
Language:Chinese
Abstract: Hypercalcemia, a common metabolic complication of malignancies, often referred to as hypercalcemia of malignancy(HCM), is associated with a high incidence and mortality rate. In 2023, the American Society for Bone and Mineral Research and the European Society of Endocrinology released the Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. This guideline aimed to address key clinical issues related to adult HCM, refractory and recurrent hypercalcemia, hypercalcemia associated with calcitriol, and hypercalcemia caused by adult parathyroid cancer. This article provides an overview of this guideline and offers some suggestions for managing related conditions in China.